New benefits for innovators and generic drug challengers

Managing Intellectual Property
October 2013

Robert Schwartz and Dana Lau discuss potential new benefits for innovators and generic drug challengers afforded by the use of inter partes review and supplemental examination.

View Attachment (PDF)